Abstract
Objectives: Elexacaftor/tezacaftor/ivacaftor (ETI) was licensed for use in Scotland in January 2022 for children aged between 6–11 years with CF and any FDA approved mutation combination. This single-centre, cohort study aimed to analyse the effects of ETI on lung health (LCI2.5) as well as spirometry and growth measures.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
